He will be instrumental in the roll-out worldwide of the Axogen portfolio..
Mr. Guido J. Neels is the Board Member of Entellus Medical, Inc. Mr. Neels has been with Essex Woodlands Health Ventures, or Essex Woodlands, since 2006, where he is now a Venture Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations....
Sentiment: Strong Buy
The recent funding means the company and it's products have been vetted with DD and this highly qualified expert in the field wants a stake in the future.So how high does it go for now and, if you still want to add, should you wait for a pullback? That is the question many may be asking.Nice to own such a stock.
Wow! I just added at $3.95 and I'm still up 72%. Nice run up on the good news about funding.
Agreed, and I like our new Board members background. From the PR "Prior to joining Essex Woodlands, he served as Chief Operating Officer of Guidant Corporation."
Yes.I added. I was tempted to add today on the breakout from the flag formation.This was a big announcement so if it's trading up, it bodes well for higher prices.
The new investor must be sold on the prospects for the products. If you read the filing, the new investor is highly qualified to be on the BOD.
I also like ARIS, ITI, DYSL, among others.
Trend, did you add back then in mid August? I sure hope you did! All I've done is the one lump sum purchase a few months ago at $3.22.
Really nice deal with added benefit of a really qualified BOD coming on board to participate in the upside to AXGN products as they begin to reach a tipping point in acceptance in this BIG market.
But we'll see how the market reacts...
I notice that if it breaks through where it is now there is no resistance until $5. This is the kind of stock that could provide such a wild ride.
There should be a lot of optimism created over the boost in revs. and that optimism could support such a move. Anyway, it's nice to think about.
As long as they keep growing revs like they just did, a tipping point should come and they will corner the market for certain medical procedures. Anyone about to buy them out would want to act before that point, I would imagine.
Right now there should be a lot of excitement energizing the company and it's stock price.
AXGN is taking market share from some pretty big players......most certainly a buyout candidate.
The major companies in the nerve repair and regeneration market are AxoGen Inc. (U.S.), Baxter International (U.S.), Boston Scientific Incorporation (U.S.), Cyberonics Inc. (U.S.), Integra Lifesciences Corporation (U.S.), Medtronic plc (U.S.), Orthomed S.A.S. (France), Polyganics B.V. (Netherland), St. Jude Medical (U.S.), and Stryker Corporation (U.S.).,,,
Sentiment: Strong Buy